CUAMC
TRDA icon

China Universal Asset Management Company’s Entrada Therapeutics TRDA Stock Holding History

China Universal Asset Management Company’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
27,778
+20,984
+309% +$201K 0.01% 350
2026
Q1 		$85.7K Buy
6,794
+566
+9% +$6.49K 0.01% 422
2025
Q4 		$64K Sell
6,228
-439
-7% -$3.7K ﹤0.01% 439
2025
Q3 		$38.7K Sell
6,667
-956
-13% -$5.59K ﹤0.01% 445
2025
Q2 		$51.2K Buy
7,623
+82
+1% +$660 ﹤0.01% 418
2025
Q1 		$68.2K Sell
7,541
-390
-5% -$4.86K 0.01% 390
2024
Q4 		$137K Buy
+7,931
New +$144K 0.01% 362

Other funds holding TRDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

China Universal Asset Management Company's TRDA Position: Q2 2026 in Review

China Universal Asset Management Company increased its Entrada Therapeutics (TRDA) stake by 309% in Q2 2026, buying an estimated $201K and bringing the position to 27,778 shares worth $204K. The position accounts for 0.01% of the portfolio, ranked #350.

China Universal Asset Management Company first reported a position in TRDA in Q4 2024 and has held it in 7 quarters since. 38 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • China Universal Asset Management Company held 27,778 shares of Entrada Therapeutics worth $204K as of Q2 2026.
  • China Universal Asset Management Company bought 20,984 Entrada Therapeutics shares in Q2 2026, an estimated $201K.
  • Entrada Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #350 holding.
  • China Universal Asset Management Company first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 38 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.